Want to see SE:SYNACT full AI Analyst Report?
SYNACT Stock Chart & Stats
kr19.44
-kr0.02(-0.11%)
At close: 4:00 PM EDT
kr19.44
-kr0.02(-0.11%)
Day’s Range― - ―
52-Week Rangekr7.05 - kr25.30
Previous CloseN/A
Volume64.35K
Average Volume (3M)175.97K
Market Cap
kr1.00B
Enterprise Valuekr1.17B
Total Cash (Recent Filing)kr14.23M
Total Debt (Recent Filing)kr929.00K
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding56,213,966
10 Day Avg. Volume90,909
30 Day Avg. Volume175,968
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low leverage gives SynAct a relatively resilient capital structure while it advances clinical programs. Limited debt reduces mandatory financing costs and repayment pressure, preserving flexibility to direct available resources toward research, trials, and future development milestones.
Focused Clinical PipelineA focused lead program can concentrate scarce clinical-stage resources around a clearly defined therapeutic thesis. Resomelagon’s oral formulation and inflammation-resolving approach provide identifiable product characteristics that could support differentiation if clinical development continues successfully.
Losses Improved From 2023The substantial improvement from the 2023 net loss indicates that financial performance is not uniformly deteriorating and that operating losses can be reduced from prior extremes. Continued cost discipline could extend this benefit while the company works toward clinical and commercial milestones.
Bears Say
No Commercial RevenueWithout commercial revenue, SynAct has no recurring operating income stream to fund research, clinical trials, or corporate expenses. Its future value therefore depends heavily on advancing resomelagon and eventually securing partnerships, licensing economics, or successful commercialization.
Sustained Cash BurnPersistent negative operating and free cash flow means the business consumes capital rather than generating funds internally. This can constrain development capacity over the next several quarters and increases reliance on external financing while clinical programs remain pre-revenue.
Funding And Dilution RiskOngoing losses and cash requirements create a structural need to obtain additional capital before a commercial product generates revenue. Future equity financing could dilute existing holders, while any funding shortfall could limit the pace or scope of clinical development.
SynAct Pharma AB News
SYNACT FAQ
What was SynAct Pharma AB’s price range in the past 12 months?
SynAct Pharma AB lowest stock price was kr7.05 and its highest was kr25.30 in the past 12 months.
What is SynAct Pharma AB’s market cap?
SynAct Pharma AB’s market cap is kr1.00B.
When is SynAct Pharma AB’s upcoming earnings report date?
SynAct Pharma AB’s upcoming earnings report date is Nov 03, 2026 which is in 28 days.
How were SynAct Pharma AB’s earnings last quarter?
SynAct Pharma AB released its earnings results on Aug 20, 2026. The company reported -kr0.392 earnings per share for the quarter.
Is SynAct Pharma AB overvalued?
According to Wall Street analysts SynAct Pharma AB’s price is currently Overvalued.
Does SynAct Pharma AB pay dividends?
SynAct Pharma AB does not currently pay dividends.
What is SynAct Pharma AB’s EPS estimate?
SynAct Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SynAct Pharma AB have?
SynAct Pharma AB has 56,213,966 shares outstanding.
What happened to SynAct Pharma AB’s price movement after its last earnings report?
SynAct Pharma AB reported an EPS of -kr0.392 in its last earnings report. Following the earnings report the stock price went down -9.93%.
Which hedge fund is a major shareholder of SynAct Pharma AB?
Currently, no hedge funds are holding shares in SE:SYNACT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SynAct Pharma AB
SynAct Pharma AB, operating through its subsidiary SynAct Pharma ApS, specializes in creating pharmaceutical interventions for the acute exacerbation of inflammatory conditions. The company's primary investigational compound, AP1189, is currently being developed for the treatment of both rheumatoid arthritis and idiopathic membranous glomerulonephritis. Additionally, SynAct Pharma maintains a collaborative research initiative with the University of Örebro, focusing on the mitigation of inflammation in vascular diseases. Established in 2012, the firm's corporate headquarters are situated in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
InDex Pharmaceuticals Holding AB
―
Active Biotech AB
―
Cantargia AB
―